

01-30 November 2023 | Online

# Ionic liquids: game changers for the development of controlled delivery systems?

Chaired by **Dr. Alfredo Berzal-Herranz** and **Prof. Dr. Maria Emília Sousa** 





Ana Júlio<sup>1,2,\*</sup>, Anaisa Sultane<sup>3</sup>, Ana S. Viana<sup>4</sup>, Catarina Rosado<sup>1</sup>, João G. Costa<sup>1</sup>, Joana P. Mota<sup>1,5</sup>, Tânia Santos de Almeida<sup>1,4</sup>, Catarina Pereira-Leite<sup>1,6</sup>

- <sup>1</sup> CBIOS-Universidade Lusófona's Research Center for Biosciences & Health Technologies, Lisbon, Portugal
- <sup>2</sup> Department of Biomedical Sciences, University of Alcalá, Ctra., Madrid, Spain
- <sup>3</sup> School of Sciences and Health Technologies, Lusófona University, Lisbon, Portugal
- <sup>4</sup> Centro de Química Estrutural, Faculdade de Ciências, Universidade de Lisboa, Lisbon, Portugal.
- <sup>5</sup> Zendal Portugal, Paredes de Coura, Portugal.

<sup>6</sup> LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal. \* Corresponding author: <u>ana.julio@ulusofona.pt</u>












01-30 November 2023 | Online



# Ionic liquids: game changers for the development of controlled delivery systems?





01-30 November 2023 | Online



#### Abstract

Poor drug solubility or loading, inflexible drug release profiles, and poor storage stability are some of the most difficult issues to surpass in the production of efficient and safe controlled delivery systems. Due to their suitable properties, ionic liquids (ILs) may be used as new functional materials to overcome these drawbacks. ILs are organic salts, that may be introduced in different types of drug delivery systems. Herein, 5 ILs were synthesized and their applicability in drug delivery systems was evaluated. Firstly, their cytotoxicity in human keratinocytes was determined, and considering these results, controlled drug delivery systems with or without ILs were developed. Each IL was incorporated at their upper concentration allowing the maintenance of cell viability. Lipidic im-plants and transfersomes (TransfersomILs) were the chosen lipid-based controlled delivery systems to investigate the impact of adding ILs. In these studies, rutin was used as model drug with poor aqueous solubility. Our results showed that ILs promoted a significantly higher drug loading, with choline-based ILs displaying better results when compared with imidazole-based ILs. The incorporation of ILs seems to modulate the drug release profile from lipidic implants. TransfersomILs had a higher association efficiency, higher total amount of drug release and better colloidal and storage stability when compared with conventional transfersomes. In conclusion, the incorporation of ILs, at non-toxic concentrations, allowed the development of more efficient delivery systems, showing that ILs may be multifunctional and valuable materials to boost performance.

Keywords: Controlled delivery systems, Ionic liquids, Lipidic implants, Rutin, TransfersomILs.







01-30 November 2023 | Online



### Model compound: Rutin





Poor aqueous solubility (0.2 mg/mL)




01-30 November 2023 | Online

# **Ionic Liquids**



Organic salts Melting point below 100 °C Anion Ionic Cation High thermal and chemical stability Liquid (+) (-) May be introduced in different solutions May be tailored to achieve the desired properties



## Development of new controlled drug delivery systems and evaluation of the impact of ILs on their performance



01-30 November 2023 | Online



# **Controlled drug delivery**

## **Advantages**

Maintenance of therapeutic dosage

Reduction of side effects

Targeted delivery

**1)** Lipidic implants

Sustained release and delivery Targeted delivery 2) Transfersomes

Easy to produce Drug protection

Low drug solubility and loading Formulation difficulties

Low stability of the developed systems Inadequate release profile



01-30 November 2023 | Online



# 1) Lipidic Implants

### Composition

Formulation	⁰∕₀ w/w									
	Dynasan® 118	Gelucire® 50/02	Sucrose	[Cho][Phe]	[Cho][Glu]	Drug				
Α		-	-	-	-					
В		-	-	0.2	-					
С		10.0	-	-	-					
D		10.0	-	0.2	-					
Ε	q.b. 100.0	-	10.0	-	-	-				
$\mathbf{F}$		-	10.0	0.2	-					
G		-	-	-	0.2					
Η		10.0	-	-	0.2					
Ι		-	10.0	-	0.2					
A <sub>Drug</sub>		-	-	-	-					
BDrug		-	-	0.2	-					
CDrug		10.0	-	-	-					
D <sub>Drug</sub>		10.0	-	0.2	-					
$\mathbf{E}_{\mathbf{Drug}}$	q.b. 100.0	-	10.0	-	-	10.0				
$\mathbf{F}_{\mathbf{Drug}}$		-	10.0	0.2	-					
GDrug		-	-	-	0.2	a D				
H <sub>Drug</sub>		10.0	-	-	0.2					
I <sub>Drug</sub>		-	10.0	-	0.2					




MDPI

01-30 November 2023 | Online

## 1) Lipidic Implants

### **Content uniformity**



Júlio A et al. Phamaceutics. 2021







01-30 November 2023 | Online

# 1) Lipidic Implants

**Drug Content** 



#### **Drug Release**



#### Júlio A et al. Phamaceutics. 2021



The studied ILs :

#### The 9th International Electronic Conference on Medicinal Chemistry

01-30 November 2023 | Online

# 1) Lipidic Implants



Article Biobased Ionic Liquids as Multitalented Materials in Lipidic Drug Implants

Ana Júlio <sup>1,2</sup>, Anaisa Sultane <sup>1</sup>, Ana Silveira Viana <sup>3</sup>, Joana Portugal Mota <sup>1</sup> and Tânia Santos de Almeida <sup>1,3,\*</sup>

Facilitate the formulation

Favour the drug incorporation

Allow to attain drug uniformity


Modify the drug release profile



01-30 November 2023 | Online

# 2) Transfersomes

- ✓ Phospholipid: soy phosphatidylcholine
- ✓ <u>EA</u>: Tween<sup>®</sup> 80
- $\checkmark$  Produced by the thin-film hydration method followed by sonication







The 9th International Electronic Conference on Medicinal Chemistry 01-30 November 2023   Online									MDPI		
2) Transfersomes Better Higher colloidal stability loading											
Formulation	Rutin (mg/mL)	IL (%)	Dh (nm)	PDI		ZP (mV)		AE (%)	LC (%)		
Water	0.0.21	0	$111 \pm 5$ $102 \pm 3$	$0.22 \pm 0.01$ $0.26 \pm 0.01$		$-31 \pm 3$		- 86.3 ± 2.1	$0.43 \pm 0.01$		
Water:[Emim][Br]	0.22	0.2	83±4*	$0.24 \pm 0.02$		-36 ± 2		$82.1 \pm 5.2$	$0.43 \pm 0.01$		
Water:[Cho][Gly]	1.50	0.2	73±2**	$0.25 \pm 0.01$		$-41 \pm 4$ *		98.1 ± 0.1 **	$3.68 \pm 0.01$ ***		
Water:[Emim][Gly]	1.60	0.2	71±1**	$0.24 \pm 0.01$		$-39 \pm 5$ *		98.7 ± 0.1 **	$3.70 \pm 0.02$ ***		
Water: [Cho][Gly]:[Emim][Br]	0.79	0.1:0.1	72±1**	$0.24 \pm 0.01$		-38±3*		93.6±0.2*	2:20 ± 0.01 ***		
Water: [Cho][Gly]:[Emim][Gly]	0.92	0.1:0.1	73±1**	$0.24 \pm 0.01$		-36±3		97.9 ± 0.1 **	1.76 ± 0.01 ***		


IL, ionic liquid; Dh, hydrodynamic diameter; PDI, polydispersity index; ZP, zeta potential; AE, association efficiency; LC, loading capacity. n = 3, mean  $\pm$  SD, \* p < 0.05, \*\* p < 0.01, and \*\*\* p < 0.001.




01-30 November 2023 | Online

# 2) Transfersomes

### Storage stability



MDPI








MDPI

01-30 November 2023 | Online

### 2) Transfersomes

#### In vitro release



Total amount of rutin released =  $1.2 \pm 0.1$  mg

Total amount of rutin released  $= 0.6 \pm 0.1$  mg

Total amount of rutin released =  $0.9 \pm 0.1$  mg

#### Júlio A et al. Nanomaterials. 2022



The studied ILs :

#### The 9th International Electronic Conference on Medicinal Chemistry

01-30 November 2023 | Online








MDF

Article

TransfersomILs: From Ionic Liquids to a New Class of Nanovesicular Systems

Ana Júlio 12, João Guilherme Costa 1, Catarina Pereira-Leite 13,# and Tânia Santos de Almeida 14, #,\*





01-30 November 2023 | Online

# MDPI

# **General Conclusions**

ILs at non-toxic concentrations facilitate the formulation procedures

> Potential of combining ILs with controlled drug delivery systems

ILs modify the release profile of the lipidic implants and allow drug uniformity The developed sustained delivery systems, containing ILs, are stable

ILs favor drug incorporation



01-30 November 2023 | Online



# **Acknowlegments**









# **Funding**



Scholarship PADDIC 2018-2019 and 2019-2020



EXPL/BTM-MAT/0112/2021 UIDB/04567/2020 and UIDP/04567/2020



LUSÓFONA

Universidad

🖗 de Alcalá

Instituto Lusôfono de Investigação e Desenvolvimento

Grant Programme FIPID 2019/2020



**THANK** 

YOU

ana.julio@ulusofona.pt